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An estimated 40 million women of reproductive age are infected with one of three species of the 36 
waterborne parasite Schistosoma (S.) spp.  Treatment with praziquantel (PZQ) via mass drug 37 
administration (MDA) campaigns is the mainstay of schistosomiasis control for populations living 38 
in endemic areas. The World Health Organization recommends that pregnant and lactating 39 
women be included in schistosomiasis MDA programs and several recent studies have evaluated 40 
the safety and efficacy of PZQ use during pregnancy. To date, there are no data describing PZQ 41 
pharmacokinetics (PK) during pregnancy or among lactating postpartum women. As part of a 42 
randomized controlled trial investigating the safety and efficacy of PZQ during human pregnancy, 43 
we examined the PK of this therapeutic drug among three distinct cohorts of women infected 44 
with S. japonicum in Leyte, The Philippines.  Specifically, we studied the PK properties of PZQ 45 
among early and late gestation pregnant women (N= 15 each) and lactating post-partum women 46 
(N=15) with schistosomiasis. We found that women in early pregnancy had increased apparent 47 
clearance and lower Area-Under-the-Curve (AUC0-24) that may be related to physiological 48 
changes in drug clearance and/or changes in oral bioavailability.  There was no relationship 49 
between body weight and apparent clearance.  The mean ± standard deviation partition ratio of 50 
plasma to breast milk was 0.36. ± 0.13 . The estimated median infant PZQ daily dose would be 51 
0.037 mg/kg ingested from breast milk, which is significantly lower than the dosage required for 52 
anti-schistosomal activity and not known to be harmful to the infant.  Our PK data do not 53 
support suggestion to delay breastfeeding 72 hours after taking PZQ. Results can help inform 54 
















Over 240 million people are infected with one of three species of the waterborne 62 
parasite Schistosoma (S.) spp., including ~40 million women of reproductive age.  More than 700 63 
million people are at risk of infection (1, 2).  Schistosomiasis caused by the most common 64 
Schistosoma spp. (i.e. S. mansoni, S. japonicum, S. haematobium) is responsible for 1.86 million 65 
disability adjusted life years (DALYS) (3). Schistosomiasis remains a significant cause of morbidity 66 
and mortality in endemic countries, despite the availability of praziquantel (PZQ), which is the 67 
only widely available anti-schistosomal drug (4).  PZQ is a first-line agent for the control of 68 
schistosomiasis in populations living in endemic areas and is administered via mass drug 69 
administration (MDA) programs (4).  Despite WHO endorsement of inclusion of pregnant women 70 
in MDA programs, this is not necessarily practised in many affected countries (5). 71 
PZQ is orally bioavailable.  Absorption is higher with carbohydrate and fat-rich foods.  72 
PZQ undergoes significant first pass metabolism and is predominantly cleared by oxidative 73 
mechanisms via CYP3A4 and CYP19A (6).  There is high inter-individual PK variability, which is 74 
further exacerbated in individuals with liver disease (7).  When PZQ was first licensed in 1979, it 75 
had not been formally studied in any pregnant or lactating women.  PZQ is classified as a Class B 76 
agent for use in pregnant women by the Food and Drug Administration (FDA).  This classification 77 
is based on demonstrated safety in laboratory animal studies, but a lack of definitive data in 78 
humans.  There is a paucity of information related to the PZQ PK in pregnant women (8) despite 79 
the high likelihood that the physiologic changes of pregnancy may affect PZQ absorption, 80 
distribution and clearance (9).  Physiological changes related to pregnancy may result in altered 81 
drug exposures, which may have an impact on the probability of therapeutic success (10).  82 
In 2002 and 2006, the World Health Organization (WHO) recommended that all 83 
schistosomiasis-infected pregnant and breastfeeding women be treated with PZQ individually or 84 
during MDA programs (11).  This was based on the expected accrued morbidity from 85 
schistosomiasis during cycles of pregnancy and lactation without treatment.  These 86 
recommendations were made despite a lack of data describing PZQ pharmacokinetics in 87 
pregnancy and lactating women.  Furthermore, there are no available data available regarding 88 
the concentration of PZQ in human breast milk following maternal treatment to support the 89 
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current recommendation to stop breastfeeding for 72 hours after taking PZQ.  Since that time, 90 
two randomized controlled trials (RCTs) (12, 13) support the safety of PZQ in pregnancy, and one 91 
(12) suggests a potential beneficial impact on the iron status of both the mother and infant (12).  92 
Although many countries have included pregnant and lactating women in MDA campaigns, many 93 
others are waiting for further data on the safety and PK  of PZQ during pregnancy and lactation 94 
(5, 14).  95 
As part of a RCT examining the safety and efficacy of PZQ during human pregnancy we 96 
examined the PK of PZQ in pregnant and lactating women infected with S. japonicum living in the 97 
northeast of the Province of Leyte, the Philippines.  The primary objective was to evaluate and 98 
compare the PK and safety of PZQ in early and late gestation pregnant women (N=15 each) and 99 
in lactating post-partum women (N=15) with schistosomiasis. 100 
101 











Study Design and Patient Demographics 104 
The study design is shown in Figure 1.  A total of 47 women that were S. japonicum 105 
positive by parasitological examination were enrolled and received a PZQ split dose of 60 mg/kg, 106 
3 hours apart (i.e. two split dosages of 30 mg/kg) (12).  Two patients in the early pregnancy 107 
group vomited shortly after receiving PZQ and did not have PK sampling performed.  This left a 108 
total of 45 patients who were divided evenly among the 3 groups: (1) early pregnancy (i.e. 12-16 109 
weeks gestation); n=15; (2) late pregnancy (i.e. 30-36 weeks gestation); n=15; and (3) lactating 110 
non-pregnant women (i.e. 5-7 months postpartum); n=15.  The weight and height for all women 111 
enrolled in the study are summarized in Table 1. 112 
 113 
Population PK of PZQ in Plasma  114 
 A population methodology was used to fit a structural PK model to the overserved 115 
plasma concentration-time data to enable robust estimates of interpatient variability.  The 116 
median and individual PZQ concentration-time profiles for each study group are shown in Figure 117 
2.  There was marked variability in the PZQ concentrations in both plasma and breast milk in all 118 
study groups.  The fact that the dosing of PZQ was split, 3 hours apart,  resulted in more than 119 
one peak concentration for each patient. 120 
The PK of PZQ in plasma and breast milk was co-modelled using a population methodology with 121 
the program Pmetrics (15) A standard 3-compartment PK model consisting of an absorptive 122 
compartment (i.e. gut), central compartment (i.e. bloodstream) and peripheral compartment 123 
(i.e. rest of the body) was initially fitted to the data before the potential impact of covariates on 124 
the PK was assessed.  The mean, median and dispersions for the population PK parameters from 125 
the base model are summarized in Table 2.  The fit of the model to the data was acceptable.  126 
There was an acceptable degree of bias and imprecision as determined by a normalized 127 
prediction distribution error (NPDE) analysis for both plasma and breast milk concentrations 128 
(data not shown; a standard VPC was not performed because women received different 129 
absolute amounts of drug).  The observed-predicted values are shown in Figure 3  and the 130 
individual plots in Supplemental figure 1.   The residuals are shown in Figure 4.  The mean of the 131 
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weighted residuals was not statistically different from zero and were normally distributed.  The 132 
Bayesian posterior estimates for each patient were calculated and these were used to assess 133 
the impact of covariates on the PK as well as estimating drug exposure of PZQ in each individual 134 
patient. 135 
There was no relationship between weight and Bayesian estimates for the apparent 136 
clearance (i.e. clearance/F), and weight and the apparent volume of the central compartment 137 
(i.e. V/F (Figure 4).  The correlation coefficient for these relationships was r = 0.0303 (95% CI -138 
0.2656, 0.3210), p-value = 0.8435 and r = 0.1617 (95% CI -0.1384, 0.4346), p = 0.2885).  Hence, 139 
covariates were not incorporated into the structural model. 140 
There were no differences in the absolute dosage received by women within the three 141 
study groups (p=0.21, Kruskal Wallis test; Figure 6A).  Furthermore, there was no relationship 142 
between the Bayesian estimates for the apparent volume of the central compartment and the 143 
study groups (Figure 6B).  However, there was a significant relationship between the apparent 144 
clearance and the stage of pregnancy.  Women in the early pregnancy group had higher 145 
apparent clearances than the other groups (Figure 6C).  Women in the early pregnancy group 146 
had faster apparent clearance of PZQ compared with postpartum women (p=0.02).  There were 147 
also differences between early and late stage pregnancy that approached, but did not achieve 148 
statistical significance (p=0.056).   149 
Women in the early pregnancy group had significantly lower AUC0-24 compared with late 150 
pregnancy (p= 0.0144) and postpartum women (p-value 0.0378).  Since there were no 151 
differences in absolute dosage received by women in these groups, the lower AUC0-24 in early 152 
pregnancy can only be explained by the faster clearance that was observed in this group or by 153 
lower oral bioavailability.  There were significant differences in the observed Cmax values 154 
between the groups.  The overall differences were statistically significant using ANOVA 155 
(p=0.019).  There was a difference between early and late pregnancy group (p=0.017 after 156 
Bonferroni correction), but not between early pregnancy and post-partum women (p=0.236) or 157 
late pregnancy and post-partum women (p=0.814).  Further evidence of the potential 158 
importance of oral bioavailability affecting drug exposure (i.e. AUC0-24) was obtained from 159 
relationship between SCL/F and V/F.  Both were highly correlated (r=0.636, 45 observations, 160 
p<0.001) suggesting F may have an impact on both parameters.  Given the uncertainty regarding 161 
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the impact of altered oxidative metabolism versus oral biovailablity as an explanation for the 162 
lower AUC0-24 we did not further complicate the structural model that was fitted to the data. 163 
 164 
Population PK of PZQ in Breast Milk  165 
 The concentration-time course of PZQ in breast milk was variable (Figure 2).  The 166 
elimination of drug in breast milk was similar to that of plasma.  The AUCplasma:AUCbreast milk 167 
mean +/- SD calculated from the Bayesian posterior estimates was 0.36. ± 0.13 with a range in 168 
the 15 lactating women of 0.19-0.55.  The average concentration in breast milk was 0.185 mg/L 169 
(i.e. AUC0-24/24).  Therefore, the estimated average ingestion of PZQ by a new-born infant that 170 
consumes 150 ml/kg of breast milk per day was approximately 0.028 mg/kg per day (i.e. 0.185 171 
mg/L * 0.15 L/kg).   172 
 The elimination half-life of PZQ from breast milk was 1.90 hours.  For a lactating woman 173 
of average weight observed in this study receiving 60 mg/kg in two divided dosages of 30 mg/kg, 174 
the estimated PZQ concentration in breast milk 24 and 48 hours post dose was 0.0004 mg/L and 175 
3 x 10-7 mg/L, respectively.  Hence, 24 hours post dose there is only 0.01% of the maximal 176 
concentration of PZQ in breast milk and at 48 hours the concentrations of drug were negligible.  177 
Monte Carlo Simulations 178 
 Monte Carlo simulations were performed using the median weight of study participants 179 
(47.9 kg).  Pmetrics was used to generate a total of 1,000 lactating women.  The concentration-180 
time profile for each patient was determined.  The 5th, 25th, 50th, 75th and 95th centiles and their 181 
95% confidence bound in plasma and breast milk is shown in Figure 7.  The AUC0-24 in plasma and 182 
breast milk was calculated from the median Bayesian posterior estimates using the trapezoidal 183 
rule in the first 24 hours following the initiation of therapy.  A plot of the simulated AUCplasma-184 
versus-AUCbreast milk is shown in Figure 7, which is overlaid with the observed AUCs from the 185 
15 lactating women in the study.  The partitioning of PZQ into breast milk was comparable 186 
between the observed data and the simulations and was approximately 30%. 187 
Adverse events 188 
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There were no severe adverse events documented in any of the women. Only two 189 
women had mild side-effects with vomiting documented within two hours of PZQ dosing and 190 
were excluded from PK analysis. The adverse events are summarized in Table 3. 191 
192 











This is the first study to describe the PK of PZQ in pregnant and lactating women infected 195 
with Schistosoma japonicum.  Women in early pregnancy had significantly lower AUC0-24 196 
compared with women in late pregnancy and lactating postpartum women.  The most likely 197 
explanation for the differences in clearance relate to pregnancy-induced increases in hepatic 198 
enzyme activity related to hormonal changes associated with pregnancy (9, 16).  The absorption 199 
of PZQ is limited by grapefruit juice suggesting the importance of oxidative mechanisms in the 200 
gut wall.  PZQ is known to undergo high first-pass metabolism.  (6, 17)  Estradiol and 201 
progesterone are both known to induce CYP3A4 in pregnancy (18) and are responsible for 202 
increased clearance of drugs such as midazolam (19, 20).  However, these changes are typically 203 
more pronounced later in pregnancy, which is not consistent with the raw data or the estimates 204 
of clearance in this study.  This observation raises that possibility that some of the changes may 205 
be related to differences in oral bioavailability in the study groups.  There were differences in 206 
Cmax between the groups (significantly lower in early pregnancy) and a high degree of 207 
correlation between SCL/F and V/F.  It is possible another pregnancy related hormone or 208 
transporter expressed in early pregnancy has an impact on clearance and drug exposure.   209 
We did not investigate the potential impact of hepatic metabolism on the PK variability of 210 
PZQ.  Liver function may be potentially altered from schistosomiasis due to S. japonicum (21).  211 
The clearance of PZQ may also be affected by pharmacogenetic polymorphisms in CYP enzymes 212 
(e.g. CYP1A2, CYP3A4, CYP2B1, CYP3A5 and CYP2C19) and/or interactions with drugs or 213 
substances taken concomitantly that induce or inhibit specific isoenzymes of the CYP system 214 
(e.g. rifampicin (22)).  Several studies have reported a decrease in CYP1A2 (23) and estrogen 215 
inhibition of CYP2C19 (24) during pregnancy, requiring a dose adjustment of certain drugs (16).   216 
The AUC0-24 is a measure of drug exposure (10) that has been used to link dosage with 217 
clinical outcomes in a recent PK/PD model in children with schistosomiasis in Uganda (25).  In a 218 
recent study [24] the mean PZQ AUC0-24 values ranged from 8.2-14.6 mg*h/L.  These values are 219 
higher than the PZQ AUC0-24 mean estimated from 60 Ugandan children 3 to 9 year of age with 220 
intestinal schistosomiasis (2.71 mg*h/L) (25).  The relevance of this observation depends on 221 
whether the pharmacodynamics of PZQ against schistosomiasis in children and pregnant women 222 
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are comparable.  While women in early pregnancy have lower AUC0-24 than women in late 223 
pregnancy or postpartum, these values are significantly higher than children receiving 224 
comparable dose for whom the efficacy of PZQ has been established.  Hence in principle, there 225 
does not appear to be any requirement to adjust the dosage according to the stage of 226 
pregnancy.  However, further studies are required to document the clinical response in pregnant 227 
women with schistosomiasis. 228 
There are limited studies on the partitioning of drugs into breast milk (26-29).  A single 229 
previous study has examined PZQ concentrations in the breast milk of healthy lactating women 230 
(30).  Our study provides further insights into the pharmacokinetics of PZQ in lactating women 231 
and the potential implications for mass drug administration programs.  Firstly, the amount of 232 
drug an infant ingests depends on the concentration of drug in breast milk.  This changes rapidly 233 
over the initial 24 hours post-dose.  The amount of drug that is ingested by an infant depends on 234 
the time of feeding relative to the administration of PZQ as well as the volume of milk that is 235 
consumed.  Using estimates for an average concentration and volume of milk, the weight-based 236 
intake of 0.037 mg/kg is significantly less than that required for therapeutic efficacy (circa 40-60 237 
mg/kg).  Second, there is relatively little variability in the AUC in breast milk.  We observed 238 
approximately a 2-fold variation in the 15 lactating women in this study and the Monte Carlo 239 
simulations suggest up to 10-fold variability may be expected if a larger number of women had 240 
been studied.  Hence, the small amount from ingestion of breast milk is unlikely to be clinically 241 
relevant.  The benefits of treating lactating women to prevent them from further developing 242 
schistosomiasis-related morbidity would seem to outweigh any potential risks.  The PK data do 243 
not support the manufacturer’s suggestion to delay breastfeeding 72 hours after taking PZQ 244 
(31). 245 
Women have been systematically excluded both from studies and MDA efforts (14).  We 246 
contend that pregnant and lactating women should not be excluded from any treatment efforts 247 
because of the demonstrated safety and efficacy of PZQ during gestation (12, 13).  This study 248 
further demonstrates there are unlikely to be clinically relevant pharmacokinetic differences in 249 
pregnant and lactating women.  Untreated schistosomiasis may lead to more severe disease and 250 
chronic disability. For example, female genital schistosomiasis may lead to infertility and 251 
disruption of a healthy reproductive life (32).  Women with intestinal schistosomiasis may have 252 
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worsening anemia and liver fibrosis.  Early treatment with PZQ is known to mitigate these late 253 
complications of schistosomiasis (33).  A concern about the theoretical risks related to PZQ has 254 
led to pregnant women being excluded from mass drug administration programs (5), however 255 
recent trials in pregnant women and this pharmacokinetic study suggest that the withholding of 256 
PZQ during pregnancy and lactation is not justified. (12, 13). Our PK results can help inform 257 
future drug efficacy studies in pregnant and lactating women with schistosomiasis. 258 
259 











Study Protocols and Permissions 262 
The study was separately approved by the ethics review board of the Research Institute 263 
of Tropical Medicine in Manila, Philippines (#2010-39) and the Institutional Review Boards from 264 
the Rhode Island Hospital in Providence, RI, USA (#415810), Boston University Medical Center in 265 
Boston, MA, USA (#H30043) and the University of California at San Diego in San Diego, CA, USA 266 
(#120559X).  Informed consent was obtained from all study participants prior to enrolment.  267 
Study site and participants 268 
The study design is summarised in Figure 1.  Eligible patients that were living in villages in 269 
northeastern Leyte, the Philippines, where S. japonicum is endemic, were identified and 270 
screened by local midwives.  Patients with at least one positive stool samples for S. japonicum 271 
were then assessed by a study obstetrician at the Remedios Trinidad Romualdez Hospital 272 
(Tacloban, Leyte, Philippines).  The methodology for detection of parasites in stool is described 273 
elsewhere (12).  Women were eligible if they met the following inclusion criteria: (1) infected 274 
with S. japonicum; (2) aged 18 years or older; (3) otherwise healthy as established by physician 275 
history, physical examination and laboratory studies; (4) had a normal obstetrical ultrasound, if 276 
pregnant; and (5) provided informed consent. Post-partum women were recruited from study 277 
villages; many had been considered for enrolment in the main RCT, but were beyond the 278 
gestational age criteria.  Eligibility criteria were the same as for pregnant women with the 279 
exception of the criterion for pregnancy.  Early pregnancy was defined as women in their 12-16 280 
week of gestation, and late pregnancy as women in their 30 -36 weeks of gestation. 281 
PZQ PK sampling 282 
Within 4 weeks of enrolment, patients received PZQ (Schering-Plough, Kenilworth, NJ, 283 
USA) in two dosages of 30 mg/kg administered approximately 3 hours apart for a total dose of 60 284 
mg/kg.  Women were given local foods that consisted of a carbohydrate-rich snack prior to PZQ 285 
dosing, as this enhances absorption of the drug (7).  After receiving PZQ, patients remained in 286 
hospital for PK sampling and monitoring for adverse events.  Patients were discharged 287 
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approximately 24 hours after the first dose.  An indwelling venous catheter was placed to draw 288 
blood samples for assay for praziquantel concentrations, which were collected at the following 289 
times: for pregnant and post-partum women prior to PZQ dosing, 1, 2, 3 (prior to administration 290 
of the 2nd dose of PZQ), 4, 5, 6, 7, 8, 9, 12, 15 and 24 hours after the first dose of PZQ.   291 
For lactating women, women hand-expressed breast milk and samples were collected 292 
within 15 minutes of collection of the blood samples scheduled for 3, 6, 9, 12, 15 and 24 hours 293 
after the first dose of PZQ.  Blood samples for toxicity monitoring (complete blood count, BUN 294 
and creatinine, liver function tests) in blood samples were collected just before the first dose, 24 295 
hours after the dose and at approximately 32 weeks gestation (early gestation subjects only) or 296 
10-14 days after the PZQ dose (late gestation and lactating post-partum subjects).  Newborns 297 
were monitored for clinical signs of toxicity until 28 days after delivery for early and late 298 
pregnancy subjects with the final study visit at 28 days of life with the study pediatrician at RTR 299 
Hospital in Tacloban. Post-partum women were seen at RTR Hospital 2 weeks after 300 
administration of study drug.  301 
Venous blood was drawn and samples were spun for 15 minutes at ~5,000 x g, 20 302 
degrees C in Eppendorf centrifuge. Plasma was removed and stored in two separate aliquots and 303 
at -80 degrees C.  Breast milk was stored at -80 degrees C. Both plasma and breast milk samples 304 
were shipped on dry ice to the University of California at San Diego (UCSD) Pediatric Clinical 305 
Pharmacology Laboratory where they were assayed for PZQ using high performance liquid 306 
chromatography–electrospray mass spectrometry according to the methods of Bonato et al (34).  307 
The lower limits of quantitation of the assay were 31.3 ng/mL for plasma and 4.3 ng/mL for 308 
breast milk.  309 
Quantification and resolution of PZQ and 4-OH PZQ in plasma and breastmilk  310 
Praziquantel (PZQ) concentrations were quantified in plasma and breast milk by liquid 311 
chromatography mass spectrometry (LC/MS), using an Agilent liquid 312 
chromatograph/autosampler interfaced with a Sciex API 4000 mass spectrometer.  Prior to 313 
analysis, proteins were removed from plasma/milk samples by precipitation with acetonitrile.  314 
Analytical grade PZQ was obtained from Sigma Aldrich.  Separation of PZQ from other matrix 315 
constituents was obtained with an isocratic HPLC mobile phase consisting of 80% methanol and 316 
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20% formic acid (0.1%) in water, in conjunction with a 2.1mm x 15cm MacMod Ace-5 C18 317 
reverse phase column. Mass transitions 313.2>203.1 1 served as quantification ions for PZQ 318 
detection, while mass transitions 313.2>174.1 served as qualification ion verification of PZQ.  319 
Quantitation was by means of external calibration using Analyst 1.6.1 software, with a 320 
qualification ion ratio threshold of ≤10% (deviation from expected).  The dynamic range of the 321 
assay was 0.1-4000 ng/mL and 2-2200 ng/mL, for plasma and breast milk, respectively. The 322 
precision of the assay was <11% and <15% at all calibration concentrations, for plasma and 323 
breast milk, respectively.  Assay accuracy was ≤ ± 8% and ≤ ± 13% for plasma and breast milk, 324 
respectively. Recovery from plasma was >91%, and >87% for breast milk, at all calibration 325 
concentrations.  326 
 327 
Population Pharmacokinetics 328 
 A population methodology was used to fit a structural model to the data.  PZQ was allowed 329 
to redistribute back to the maternal plasma without terminal elimination via expression of breast 330 
milk.  The model was structured in this way to avoid an unidentifiable solution, but also because 331 
the excretion of drug in breast milk was assumed to be minimal and the equilibrium was rapid.  332 
The structural model took the form: 333 
 334 
       Eq. 1 335 
  Eq. 2 336 
       Eq. 3 337 
       Eq. 4 338 
 339 
Where: XP(1), XP(2), XP(3) and XP(4) is the rate of change of PZQ mass in the gut, central 340 
compartment, peripheral compartment and breast milk, respectively.  Similarly, X(1), X(2), X(3) 341 
and X(4) represent the mass (mg) of PZQ in the respective compartments.  Bolus refers to the 342 
oral administration of PZQ; SCL is the first-order clearance of PZQ from the central compartment, 343 
Vc is the volume of the central compartment; Kpc, Kpc, Kcb and Kbc are the first-order 344 
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intercompartmental rate constants.  A lag function (not shown in the differential equations) was 345 
applied between the oral administration of PZQ and the appearance of drug in the central 346 
compartment.  347 
 348 
The output equations were given by: 349 
Y(1)=X(1)/Vc (for the plasma concentrations) 350 
Y(2)=X(4)/Vb (for the concentrations in breast milk) 351 
Where Vb is the volume of breast milk compartment. 352 
 353 
The fit of the model to the data was informed by a linear regression of observed-354 
predicted values before and after the Bayesian step, the log likelihood ratio and a normalised 355 
prediction distribution error.  The latter was used in place of a more traditional visual predictive 356 
plot because women received different dosages of PZQ.  Both the mean and median parameter 357 
values were interrogated to see which measure of central tendency better described the data.  358 
Weighted residuals were calculated and plotted against predicted concentrations, time and 359 
assessed for normality using D’Agostino, Shapiro-Wilk and Kolmogorov-Smirnof tests  Drug 360 
exposure was quantified in terms of the AUC0-24 as previously described by us(25).This was 361 
estimated using the trapezoidal rule using Pmetrics and estimated from the Bayesian posterior 362 
estimates from each study patient or from simulated patients. 363 
 364 
Statistical Modelling 365 
 366 
The Bayesian estimates for clearance and AUC0-24 were modelled for study groups using 367 
univariate analysis of variance (ANOVA). Since both Bayesian estimates for clearance and AUC0-24  368 
were not distributed normally, they were fitted on natural log scale. The estimated means of 369 
clearance and AUC0-24  between individual study groups were compared in a post-hoc analysis 370 
using Tukey’s Test, and the reported p-values were corrected for multiple comparisons. 371 
 372 
373 
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47.6 (8.12) 51.5 (7.08) 46.6 (7.40) 48.5 (7.69) 
Height (cm)   
Mean (SD) 
152.0 (5.45) 149.8 (5.63) 152.3 (4.56) 151.4 (5.24) 
Age (Years)     
 Mean (SD) 23.8 (5.98) 26.5 (6.61) 26.5 (6.65) 25.5 (6.39) 
 Median 21.0 25.0 24.0 24.0 
 Min, Max 18, 37 18, 37 20, 44 18, 44 
Ethnicity  N (%)     
Non-Hispanic nor Non-Latino 17 (100.0) 15 (100.0) 15 (100.0) 47 (100.0) 
Hispanic or Latino 0 (0) 0 (0) 0 (0) 0 (0) 
Race  N (%)     
 American Indian/Alaskan Native 0 (0) 0 (0) 0 (0) 0 (0) 
 Asian 17 (100.0) 15 (100.0) 15 (100.0) 47 (100.0) 
 Hawaiian/Pacific Islander 0 (0) 0 (0) 0 (0) 0 (0) 
 Black/African American 0 (0) 0 (0) 0 (0) 0 (0) 
 White 0 (0) 0 (0) 0 (0) 0 (0) 
 Multi-Racial 0 (0) 0 (0) 0 (0) 0 (0) 
Number of prior live births  N (%)     
0 6 (35.3) 4 (26.7) 1 (6.7) 11 (23.4) 
1 - 5 10 (58.8) 9 (60.0) 11 (73.3) 30 (63.8) 
6 - 10 1 (5.9) 2 (13.3) 3 (20.0) 6 (12.8) 
> 10 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Current smoking status  N (%)     
No 17 (100.0) 15 (100.0) 13 (86.7) 45 (95.7) 
Yes 0 (0.0) 0 (0.0) 2 (13.3) 2 (4.3) 
Current alcohol consumption  N (%)     
No 5 (29.4) 2 (13.3) 2 (13.3) 9 (19.1) 
Yes 12 (70.6) 13 (86.7) 13 (86.7) 38 (80.9) 
Intensity of S. japonicum infection  N 
(%) 
    
Low (<100 eggs per gram of stool) 16 (94) 15 (100) 15 (100) 46 (97.8) 



































Moderate (100-399 eggs per gram 
of stool ) 
1 (6) 0 (0) 0 (0) 1 (2.2) 
Heavy (≥ 400  eggs per gram of 
stool) 
0 (0) 0 (0) 0 (0) 0 (0) 












Table 2. Parameter Values from the population PK model  501 
 502 




Ka (h-1) 2.012 0.395 4.301 213.750 
SCL/F (L/h) 324.075 277.447 175.373 54.115 
Vc/F (L) 183.006 142.618 93.211 50.933 
Kcp (h-1) 19.313 18.941 10.167 52.644 
Kpc (h-1) 15.816 13.996 9.447 59.733 
Kcb (h-1) 18.750 19.301 9.387 50.067 
Kbc (h-1) 17.816 17.077 7.845 44.031 
Vb/F (L) 612.130 563.802 395.661 64.637 
Lag (h) 0.772 0.868 0.233 30.202 
 503 
 504 
aNote: Parameters are as follows: Ka is the first-order absorption constant; SCL/F is the apparent 505 
clearance; Vc/F and Vb/F are the apparent volumes of the central and breast compartments, 506 
respectively; Kcp, Kpc, Kbc and Kcb are the first-order intercompartmental rate constants; Lag is 507 
the delay between drug administration and the appearance of drug in the central compartment. 508 
509 
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 510 
Table 3. Adverse Events by severity and cohort  511 
 512 
 Cohort 1 (N=17) Cohort 2 (N=15) Cohort 3 (N=15) 


























































































































































































































































































































N=Number of subjects in population; n=Number of subjects with at least one occurrence of an 513 
adverse event in the specified category. 514 
 515 
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Figure 2: Median and individual PZQ concentration time profiles.   
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 567 
Figure 3. The observed-predicted plots for the PZQ concentrations in plasma (Panel A) and breast 568 
milk (Panel B) after the Bayesian step.  The median parameter values for each patient have been 569 
used.  The observed-predicted data is plotted on a log-log plot for both outputs and is shown in 570 
the inserts.  The regression line for plasma in Panel A is given by Observed = 571 
0.016+1.04*Predicted; r2=0.604.  The regression line for breast milk in Panel B is given by 572 

















Figure 4.  Residual plots for plasma concentrations.  The average residuals did not vary from zero; 581 
p=0.88 for weighted residual error versus Predicted concentrations (far left panel) and for 582 
weighted residual error versus Time (middle panel).  The solid line Panel A and Panel B is the 583 
loess regression.  The residuals were normally distributed as assessed using D’Agostino, Shapiro-584 

















Figure 5. The relationship between Weight and Clearance/F (Panel A) and Weight and Volume/F (Panel B).  593 
The volume is the volume of the central compartment.  Neither relationship is statistically significant with 594 























Bustinduy et al.                                                                                                       PZQ PK in pregnancy 
 30 
 611 
Figure 6. Box plots showing the relationship between various stages of pregnancy and dose (Panel A), 612 
Volume of the central compartment/F (Panel B), Clearance/F (Panel C) and the area under the 613 
concentration-time curve (AUC0-24) in Panel D.  There was no relationship between the stage and 614 
pregnancy and the absolute dose (mg) and volume/F (p=0.2072 and 0.626, respectively).  Women in the 615 
early pregnancy group have a higher clearance/F than other women (p=0.016 for all groups) and a lower 616 
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 626 
Figure 7.  Monte Carlo simulations showing the drug exposure in plasma (Panel A), breast milk (Panel B) 627 
from 1,000 lactating women.  Each line represents the 5th, 25th, 50th, 75th and 95th centiles and the grey 628 
representing the confidence interval around each centile.  In Panel C the AUC0-24 in plasma versus breast 629 
milk in each simulated woman is shown with black open circles.   The AUC0-24 from each of the 15 patients 630 




 on July 9, 2020 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
